1. Home
  2. WMB vs VRTX Comparison

WMB vs VRTX Comparison

Compare WMB & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Williams Companies Inc. (The)

WMB

Williams Companies Inc. (The)

N/A

Current Price

$73.23

Market Cap

91.3B

Sector

Utilities

ML Signal

N/A

Logo Vertex Pharmaceuticals Incorporated

VRTX

Vertex Pharmaceuticals Incorporated

N/A

Current Price

$459.75

Market Cap

115.7B

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
WMB
VRTX
Founded
1908
1989
Country
United States
United States
Employees
N/A
N/A
Industry
Natural Gas Distribution
EDP Services
Sector
Utilities
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
91.3B
115.7B
IPO Year
2002
2006

Fundamental Metrics

Financial Performance
Metric
WMB
VRTX
Price
$73.23
$459.75
Analyst Decision
Buy
Buy
Analyst Count
17
27
Target Price
$74.94
$526.79
AVG Volume (30 Days)
6.5M
1.3M
Earning Date
05-12-2026
05-15-2026
Dividend Yield
2.83%
N/A
EPS Growth
17.58
836.54
EPS
2.14
15.32
Revenue
$11,950,000,000.00
$2,488,652,000.00
Revenue This Year
$7.37
$10.79
Revenue Next Year
$10.19
$10.14
P/E Ratio
$34.62
$29.80
Revenue Growth
13.78
46.20
52 Week Low
$51.58
$362.50
52 Week High
$76.87
$519.68

Technical Indicators

Market Signals
Indicator
WMB
VRTX
Relative Strength Index (RSI) 57.11 44.07
Support Level $56.46 $451.45
Resistance Level $76.87 $465.98
Average True Range (ATR) 1.37 12.33
MACD -0.37 -3.25
Stochastic Oscillator 22.80 18.51

Price Performance

Historical Comparison
WMB
VRTX

About WMB Williams Companies Inc. (The)

Williams operates the Transco pipeline, which connects the Gulf Coast to the Northeast United States. It has additional natural gas transmission pipelines connecting the Rockies to the Pacific Northwest and midcontinent. At the field level, it operates substantial gathering and processing assets in Appalachia and other basins. The company has also struck several power supply agreements.

About VRTX Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Share on Social Networks: